Skin Microbiome Articles & Analysis
11 news found
KINS is a health technology company that supports the care of microbiome, which is responsible for health and vitality throughout the body, and accelerates research while building and analyzing databases of microbiome samples from skin, scalp, intestines, and more. The company recently expanded its business to include the ...
("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...
(NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. ...
ByBiomX
"We have demonstrated the clinical efficacy of DBI-001 in tinea pedis and have significantly deepened our industry leading understanding of the skin microbiome and how to develop live biotherapeutics as drug products." ...
DermBiont's Phase 2a trial was primarily designed as a safety and tolerability study with a secondary endpoint to demonstrate that DBI-001 could have a favorable effect on the skin microbiome of atopic dermatitis patients. A single topical application of investigational drug product showed DBI-001 to be well tolerated with no safety issues while also resulting in ...
Company studies have also shown the potential antimicrobial mechanism of action that contribute to the reduction of pathogenic bacteria infecting the established skin lesions," said Board of Director, Dr. Annalisa Jenkins, MBBS MRCP. ...
Company studies have also shown the potential antimicrobial mechanism of action that contribute to the reduction of pathogenic bacteria infecting the established skin lesions," said Board of Director, Dr. Annalisa Jenkins, MBBS MRCP. ...
“Current therapies for atopic dermatitis can cause side effects such as stinging, burning, and thinning of skin, especially in pediatric patients. B244’s innovative nature represents a novel therapeutic opportunity to address the significant market need and to impact the lives of ...
Atopic dermatitis or eczema is a recurring inflammatory skin disease which poses a significant burden on patients’ quality of life. ...
"With the company rapidly accelerating its innovative Ammonia Oxidizing Bacteria platform across multiple applications, we are that much closer to achieving our long-term goals within the microbiome space." Professor Klaus Dugi Dr. Dugi has over 25 years of experience mainly in the field of medicine. ...
"I am honored to serve as the Chairman of AOBiome's Board of Directors at this important time for the company," said Dr. Wang. "Microbiome-based therapies are accelerating at a very fast pace with many new potential applications. ...